Neuralace (neuroimplant)

For 2023, Blackrock Neurotech has a medical specialty, which makes it possible to position the company in the media field as a civil project. The company can attract funding from both public and private investors, and be quite flexible in its management decisions. At the same time, part of the work, with a high probability, is carried out on military topics in the interests of the Pentagon.

The use of chips can be divided into two directions. The first is direct control of the brain activity of the population, which will be a popular decision when introducing a system of social rating and unconditional basic income (DB). The bundle of social rating and DBD is a key element of the globalist agenda.

And the second direction is military-applied tasks using AI.

History

2022: Neuroimplant announcement

In mid-November 2022, brain-computer interfaces manufacturer Blackrock Neurotech unveiled its next-generation Neuralace neurointerface. According to the developers, a flexible electrode with an ultra-high number of channels provides an opportunity to look into innovative technology that will become the basis for future developments.

Blackrock Neurotech's time-tested NeuroPort Array, has been used in human neuroimplants since 2004 and has provided many of the most significant advances in the field. In clinical trials, patients using neuroimplant from Blackrock Neurotech have restored tactile functions, movements of their own limbs and prostheses, and the ability to control digital devices despite diagnoses of paralysis and other neurological disorders.

Presented neuroimplant with 10 thousand neurochannels

Neuralace demonstrates our belief in where science should move to unlock the true potential of neuroimplants. This conceptual technology is the beginning of Blackrock Neurotech's journey to collect data from the entire brain, which will change the way neurological disorders are treated. We are actively developing new treatments for anxiety, depression and other neurological disorders that will allow this technology to be used, "said Blackrock Neurotech co-founder and CEO Marcus Gerhardt.

Neuroimplant allows patients to perform complex functions without the help of assistive technologies for areas such as vision and memory restoration, performance prediction and treatment of mental disorders such as depression will have to interact with more neurons.

People with paralysis or nervous system disorders can drink, eat, send emails and operate robotic mechanisms. People have the ability to type at a speed of 90 characters per minute. The text will be 94% correct. Individual subjects can use graphics programs and play video games.

Neuralace is designed to meet this need with more than 10,000 neurochannels and an entire scalable system integrated into a flexible chip with a lace structure, it can collect data orders of magnitude more than existing electrodes, which allows you to exponentially increase capabilities and intuition.

Due to its fine structure, Neuralace can adjoin the fractures and furrows of the brain, increasing the surface area from which the data is collected. The adaptable structure of Neuralace also means improved biocompatibility. The body's immune response has been a challenge for all neural implants, but a porous neuroimplant form factor will provide more natural integration with neural tissue, maintaining the flow of cellular fluids and diffusion of biomolecules that might otherwise trigger an immune response or inflammation.

For November 2022, Blackrock Neurotech is preparing its NeuroPort array-based neuroimplant, MoveAgain, for commercial launch as a medical device. The company expects Neuralace to become an affordable tool for the neuroscience research community by 2024, joining its extensive portfolio of clinical and research electrodes on the market.^[1]

The total volume of clinical trials for May 2023 is more than 30,000 days, and the number of scientific publications exceeded 1,700.

Notes